share_log

Morgan Stanley Maintains Underweight on Evofem Biosciences, Lowers Price Target to $0.75

Morgan Stanley Maintains Underweight on Evofem Biosciences, Lowers Price Target to $0.75

摩根士丹利維持對Evofem Biosciences的減持,將目標股價下調至0.75美元
Benzinga Real-time News ·  2022/07/15 10:28

Morgan Stanley analyst Jeffrey Hung maintains Evofem Biosciences (NASDAQ:EVFM) with a Underweight and lowers the price target from $2 to $0.75.

摩根士丹利分析師傑弗裏·洪維持Evofem Biosciences(納斯達克股票代碼:EVFM)的減持,並將目標股價從2美元下調至0.75美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論